文献速递肿瘤 PET/CT核素与放射性配体治疗放射性药物与辐射防护

68Ga-PSMA-11 PET/CT 在前列腺癌根治术后生化复发且 PSA 低于 1.0 ng/mL 的 270 例患者中的复发分布及其对挽救性放疗计划的影响

68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.
PubMed 文献 · J Nucl Med · 2017-11-09

该研究对 270 例根治性前列腺切除术后未接受过放疗、PSA<1.0 ng/mL 的生化复发患者行 68Ga-PSMA-11 PET/CT,并在盲于 PET 的情况下按 RTOG 共识勾画临床靶区。结果显示 132/270(49%)PET/CT 阳性,52/270(19%)存在未被共识靶区覆盖的 PSMA-11 阳性病灶,提示对挽救性放疗计划有重要影响。

要点

  • 270 例术后生化复发且 PSA<1.0 ng/mL 患者中,132 例(49%)68Ga-PSMA-11 PET/CT 阳性。
  • 52/270(19%)存在未被 RTOG 共识临床靶区覆盖的 PSMA-11 阳性病灶。
  • 共识靶区外最常见部位为骨(23/52,44%)和直肠旁淋巴结(16/52,31%)。

核心结论

  • 对 270 例前列腺癌早期生化复发(PSA<1.0 ng/mL)患者的 68Ga-PSMA-11 PET/CT 事后分析提示,52 例(19%)的挽救性放疗计划受到重要影响。
  • 作者认为该发现值得开展随机影像试验,比较有或无 68Ga-PSMA-11 PET/CT 的挽救性放疗对临床结局的潜在获益。

研究设计与样本

  • 对 270 例根治性前列腺切除术后未接受过放疗、PSA<1.0 ng/mL 的生化复发患者进行的事后分析,这些患者来自 4 家机构并按意向治疗人群纳入。
  • 由对 PET 部分设盲的放疗科医师在 PET/CT 的 CT 数据集上勾画包含前列腺床和盆腔淋巴结的 RTOG 共识临床靶区。
  • 由核医学科医师分析 68Ga-PSMA-11 PET/CT 图像;未被基于共识临床靶区的计划体积覆盖的 PSMA-11 阳性病灶被视为对治疗计划有潜在重要影响。

主要发现

  • 68Ga-PSMA-11 PET/CT 时中位 PSA 为 0.48 ng/mL(范围 0.03–1 ng/mL)。
  • 270 例中 132 例(49%)68Ga-PSMA-11 PET/CT 结果为阳性。
  • 270 例中 52 例(19%)至少有 1 个未被共识临床靶区覆盖的 PSMA-11 阳性病灶。
  • 270 例中 33 例(12%)有盆腔外 PSMA-11 阳性病灶,19 例(7%)有盆腔内但未被共识临床靶区覆盖的 PSMA-11 阳性病灶。
  • 共识靶区外最常见的 2 个 68Ga-PSMA-11 阳性病灶部位为骨(23/52,44%)和直肠旁淋巴结(16/52,31%)。

关键数值与推荐

  • 阳性判定:68Ga-PSMA-11 PET/CT 阳性指检出 PSMA-11 阳性病灶。
  • 覆盖判定:以 RTOG 共识临床靶区(含前列腺床和盆腔淋巴结)勾画的计划体积为参照,其外病灶计为潜在重要影响。
  • PSA 条件:纳入时血清 PSA<1.0 ng/mL,PET/CT 时中位 0.48 ng/mL(范围 0.03–1 ng/mL)。

临床怎么用

  • 原文结论认为,在此类早期生化复发患者中,68Ga-PSMA-11 PET/CT 对挽救性放疗计划有重要影响。
  • 作者提出需开展随机影像试验,评估有或无 68Ga-PSMA-11 PET/CT 的挽救性放疗对临床结局的潜在获益。
  • 原文未据此给出关于挽救性放疗靶区勾画或是否加用 68Ga-PSMA-11 PET/CT 的具体推荐。

局限性

  • 原文明确为事后分析(post hoc analysis)。
  • 原文在结论中提出该发现值得开展随机影像试验,以检验其潜在获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Target volume delineations for prostate cancer (PCa) salvage radiotherapy (SRT) after radical prostatectomy are usually drawn in the absence of visibly recurrent disease. 68Ga-labeled prostate-specific membrane antigen (PSMA-11) PET/CT detects recurrent PCa with sensitivity superior to standard-of-care imaging at serum prostate-specific antigen (PSA) values low enough to affect target volume delineations for routine SRT. Our objective was to map the recurrence pattern of PCa early biochemical recurrence (BCR) after radical prostatectomy with 68Ga-PSMA-11 PET/CT in patients with serum PSA levels of less than 1 ng/mL, determine how often consensus clinical target volumes (CTVs) based on the Radiation Therapy Oncology Group (RTOG) guidelines cover 68Ga-PSMA-11 PET/CT-defined disease, and assess the potential impact of 68Ga-PSMA-11 PET/CT on SRT. Methods: This was a post hoc analysis of an intention-to-treat population of 270 patients who underwent 68Ga-PSMA-11 PET/CT at 4 institutions for BCR after prostatectomy without prior radiotherapy at a PSA level of less than 1 ng/mL. RTOG consensus CTVs that included both the prostate bed and the pelvic lymph nodes were contoured on the CT dataset of the PET/CT image by a radiation oncologist masked to the PET component. 68Ga-PSMA-11 PET/CT images were analyzed by a nuclear medicine physician. 68Ga-PSMA-11-positive lesions not covered by planning volumes based on the consensus CTVs were considered to have a potential major impact on treatment planning. Results: The median PSA level at the time of 68Ga-PSMA-11 PET/CT was 0.48 ng/mL (range, 0.03-1 ng/mL). One hundred thirty-two of 270 patients (49%) had a positive 68Ga-PSMA-11 PET/CT result. Fifty-two of 270 (19%) had at least one PSMA-11-positive lesion not covered by the consensus CTVs. Thirty-three of 270 (12%) had extrapelvic PSMA-11-positive lesions, and 19 of 270 (7%) had PSMA-11-positive lesions within the pelvis but not covered by the consensus CTVs. The 2 most common 68Ga-PSMA-11-positive lesion locations outside the consensus CTVs were bone (23/52, 44%) and perirectal lymph nodes (16/52, 31%). Conclusion: Post hoc analysis of 68Ga-PSMA-11 PET/CT implied a major impact on SRT planning in 52 of 270 patients (19%) with PCa early BCR (PSA < 1.0 ng/mL). This finding justifies a randomized imaging trial of SRT with or without 68Ga-PSMA-11 PET/CT investigating its potential benefit on clinical outcome.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Calais J, Czernin J, Cao M, et al. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. J Nucl Med. 2017. PMID: 29123013. doi:10.2967/jnumed.117.201749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。